Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Josep Tabernero, M.D., Ph.D.


Josep Tabernero, M.D., Ph.D. is the Director of the Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical Oncology Department of Vall d’Hebron University Hospital. He is also Co-Director of VHIO´s Gastrointestinal and Endocrine Tumours Group and the Research Unit for Molecular Therapy of Cancer (UITM). Dr. Tabernero is Principal Investigator of several phase I pharmacodynamic studies and translational projects with molecular targeted therapies, as well as phase II and III studies with novel chemotherapeutics. Dr. Tabernero previously served as ESMO president for the 2018-2019 term and currently serves as a member of several editorial boards, including Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer, and Annals of Oncology. He received his M.D. and Ph.D. from the Universitat Autònoma de Barcelona, Spain.